The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.
The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.
The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.
The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.
[EN] NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS<br/>[FR] NOUVEAUX COMPOSÉS D'ACIDE PYRROLIDINYL ET TÉTRAHYDRO-2 H-PYRANYL ACÉTIQUE À SUBSTITUTION PAR TRIAZOLE-PYRIDINE UTILISÉS EN TANT QU'ANTAGONISTES DE LPA
申请人:VIVA STAR BIOSCIENCES SUZHOU CO LTD
公开号:WO2022232459A1
公开(公告)日:2022-11-03
This application relates to novel triazole-pyridine substituted pyrrolidinyl, tetrahydro-2H-pyranyl, cyclohexyl, and piperidinyl acetic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptors (LPA).